Literature DB >> 10146988

Therapeutic substitution: an option for cost-effective prescribing?

S R Shulman, W Gouveia.   

Abstract

Mesh:

Year:  1993        PMID: 10146988     DOI: 10.2165/00019053-199303040-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  8 in total

1.  Improving the quality and cost-effectiveness of prescribing.

Authors:  J Avorn
Journal:  Pharmacoeconomics       Date:  1992       Impact factor: 4.981

2.  Therapeutic interchange as a cost-containment measure {editorial}.

Authors:  L E Achusim
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

Review 3.  Trends in retail prescription expenditures.

Authors:  S W Schondelmeyer; J Thomas
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

4.  Coordinated care and public programs.

Authors:  G R Wilensky; L F Rossiter
Journal:  Health Aff (Millwood)       Date:  1991       Impact factor: 6.301

5.  Therapeutic substitution in the health maintenance organization outpatient environment.

Authors:  P L Doering; W L Russell; W C McCormick; D L Klapp
Journal:  Drug Intell Clin Pharm       Date:  1988-02

6.  Therapeutic substitution and formulary systems. American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

Review 7.  Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution.

Authors:  W H Frishman
Journal:  Am Heart J       Date:  1987-05       Impact factor: 4.749

Review 8.  Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients.

Authors:  R A Levy; D L Smith
Journal:  DICP       Date:  1989-01
  8 in total
  2 in total

1.  Therapeutic dilemmas. An approach to the management of expensive pharmaceutical advances.

Authors:  L Y Nishimura; R Shane
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

2.  Pharmacoeconomic aspects in the treatment of curable and incurable cancer.

Authors:  V Jønsson; S R Clausen; M M Hansen
Journal:  Pharmacoeconomics       Date:  1995-10       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.